Int J Clin Oncol DOI 10.1007/s10147-014-0746-7
ORIGINAL ARTICLE
Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration‑resistant prostate cancer Keisuke Shigeta · Takeo Kosaka · Satoshi Yazawa · Yota Yasumizu · Ryuichi Mizuno · Hirohiko Nagata · Kazunobu Shinoda · Shinya Morita · Akira Miyajima · Eiji Kikuchi · Ken Nakagawa · Shintaro Hasegawa · Mototsugu Oya
Received: 7 April 2014 / Accepted: 19 August 2014 © Japan Society of Clinical Oncology 2014
Abstract Background The aim of this study is to identify factors that increase the occurrence of severe neutropenia (SN) and febrile neutropenia (FN) during docetaxel treatment for castration-resistant prostate cancer (CRPC). Methods We retrospectively reviewed 258 courses during the first three cycles among 95 patients. Docetaxel at a dose of 75 mg/m2 was administered every 3 or 4 weeks. Patient background, laboratory data, and bone scan results were collected to assess predictive factors for SN and FN. We defined SN as an absolute neutrophil count (ANC) of 20 % of FN) or intermediate risk (10–20 % of FN) regimen in the G-CSF recommendation, which indirectly categorizes docetaxel as a low-risk (
ORIGINAL ARTICLE
Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration‑resistant prostate cancer Keisuke Shigeta · Takeo Kosaka · Satoshi Yazawa · Yota Yasumizu · Ryuichi Mizuno · Hirohiko Nagata · Kazunobu Shinoda · Shinya Morita · Akira Miyajima · Eiji Kikuchi · Ken Nakagawa · Shintaro Hasegawa · Mototsugu Oya
Received: 7 April 2014 / Accepted: 19 August 2014 © Japan Society of Clinical Oncology 2014
Abstract Background The aim of this study is to identify factors that increase the occurrence of severe neutropenia (SN) and febrile neutropenia (FN) during docetaxel treatment for castration-resistant prostate cancer (CRPC). Methods We retrospectively reviewed 258 courses during the first three cycles among 95 patients. Docetaxel at a dose of 75 mg/m2 was administered every 3 or 4 weeks. Patient background, laboratory data, and bone scan results were collected to assess predictive factors for SN and FN. We defined SN as an absolute neutrophil count (ANC) of 20 % of FN) or intermediate risk (10–20 % of FN) regimen in the G-CSF recommendation, which indirectly categorizes docetaxel as a low-risk (
